TAK 603

BACKGROUND The therapeutic efficacy of the regulation of T helper (Th)-1-predominant immune responses remains to be investigated… Expand

BACKGROUND AND AIM Sarcoidosis is immunologically characterized by highly enhanced Th1 responses in active stage. TAK-603 is a… Expand

Graft-vs-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation. GVHD… Expand

Acute graft-versus-host diseases (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic bone marrow… Expand

In the course of our studies aimed at obtaining new drugs for treatment of bone and joint diseases, chemical modification of the… Expand

A new antirheumatic, TAK-603, shows nonlinear pharmacokinetics in both animals and humans. To elucidate the mechanism of these… Expand

The disposition of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4- triazol-1-ylmethyl) quinoline-3-carboxylate (CAS 158146… Expand

The metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmeth yl)quinoline -3-carboxylate (1, TAK-603… Expand

We have shown that TAK-603, a new anti-rheumatic drug, is more effective in animal models in which cellular immunity plays a… Expand

We investigated the pharmacological activities of a newly synthesized anti-rheumatic drug, TAK-603. (1) In vivo: In adjuvant… Expand